Pathology of the heart valves, both primary and secondary, can cause or contribute to heart failure (HF). Primary valve disease, such as aortic stenosis, may cause or worsen HF by increasing left ventricular (LV) afterload and causing LV hypertrophy and remodelling. Secondary (functional) mitral regurgitation can be attributed to LV dilation/dysfunction or atrial/annular dilatation; both functional aetiologies are associated with poor prognosis in patients with HF. Similarly, significant functional tricuspid regurgitation is associated with poor outcomes in HF patients with either preserved or reduced LV ejection fraction.
Optimal medical therapy and referral to a multidisciplinary heart team are important in the management of patients with valvular heart disease and HF, but what valve interventions are available and which patients benefit most?
These are some of the questions that will be discussed by an expert faculty in one of today’s symposia, chaired by Professor Piotr Ponikowski (Wroclaw Medical University, Poland) and Professor Rebecca Hahn (Columbia University Medical Center, New York, USA).
Transcatheter aortic valve implantation and surgical aortic valve replacement will be discussed by Professor Helene Eltchaninoff (Rouen University Hospital and University of Rouen, France), while Professor Joerg Hausleiter (Ludwig-Maximilians University, Munich, Germany) will review mitral valve interventions, including percutaneous edge-to-edge mitral valve repair. Professor Georg Nickenig (Heartcenter Bonn, University Hospital Bonn, Germany) will describe how transcatheter strategies and surgery may be used in patients with tricuspid regurgitation and HF.
Want to know more? Add this session to your favourites then watch it live or on demand.
You will also find the latest recommendations for management of patients with HF and valvular heart disease in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic HF, now published in the European Heart Journal.